ETF · Invesco
SBIX Invesco NASDAQ Biotech UCITS ETF
ISIN IE00BQ70R696London Stock Exchange: SBIXInvesco Ltd.
- Healthcare
- ETF
- ISA
- SIPP
- Accumulating
Latest close
LSE£56.52
on
- Ongoing charge
- 0.40% a year
- Fund size
- £503m
As of , at least 15 min delayed
At a glance
As of 13/11/2026, SBIX (Invesco NASDAQ Biotech UCITS ETF, ISIN IE00BQ70R696) closed at £56.52 on the London Stock Exchange. Its ongoing charge is 0.40% a year (about £40 on £10,000). Over the five years to 13/11/2026 its total return was +57.3%, or +22.8% after UK CPIH inflation.
Past returns
- 1 year to 13/11/2026
- +33.3%
- +28.6% after inflation (UK CPIH)
- 3 years to 13/11/2026
- +86.5%
- +68.5% after inflation (UK CPIH)
- 5 years to 13/11/2026
- +57.3%
- +22.8% after inflation (UK CPIH)
£1,000 put in five years ago would have been worth about £1,573 on 13/11/2026 — about £1,228 in today’s spending power, once price rises are taken out. Past performance is not a guide to future returns.
Returns: as reported (delayed data). Inflation: UK CPIH, latest month published.
How we work it out:ReturnsReturns after inflationTotal returnReal returnCPIH
Calendar-year and 12-month returns
Calendar-year returns of Invesco NASDAQ Biotech UCITS ETF in pounds (price, with income reinvested in the fund): 2026 to 13/11/2026 +28.8%. Returns of Invesco NASDAQ Biotech UCITS ETF in pounds (price, with income reinvested in the fund) over the 12 months to 30/09/2026: +43.7%.
| Year | Return | After inflation | Return shown as a bar |
|---|---|---|---|
| to | +28.8% | +24.7% |
| 12 months to | Return | After inflation |
|---|---|---|
| from | +43.7% | +38.7% |
As of , inflation: UK CPIH
How we work it out:Calendar-year returnsWhat a calendar-year return isAccumulating and distributing
Risk: volatility and largest fall
Volatility (annualised)
19.0%over 1 year
Annualised from weekly returns. Higher means bumpier.
- Largest fall since August 2025
- −5.9%
- From to
- Below its highest weekly close since August 2025
- 0.9%
- High of , latest
In words: Volatility of Invesco NASDAQ Biotech UCITS ETF in pounds, annualised from weekly returns to 13/11/2026: 19.0% over 1 year. Largest fall in the price of Invesco NASDAQ Biotech UCITS ETF since August 2025, in pounds: −5.9% from 03/07/2026 to 31/07/2026. On 13/11/2026 the price of Invesco NASDAQ Biotech UCITS ETF was 0.9% below its highest weekly close since August 2025 (30/10/2026), in pounds.
As of , price, with income reinvested in the fund
How we work it out:Risk figuresFallsVolatilityLargest fall
Charges compared with similar funds
- Ongoing charge
- 0.40%
- a year
- On £10,000
- £40
- a year, roughly
- Over five years
- £198
- of £10,000, before growth
- 19 charge less
- 2 the same
- 7 charge more
Ongoing charge of Invesco NASDAQ Biotech UCITS ETF 0.40% a year. Compared on 14/11/2026, 7 of the 28 other healthcare funds charge more, 2 the same and 19 less (share classes counted once).
As of
A lower charge is not a promise of a higher return: what the fund holds matters more.
As of
Read more:Ongoing charge (OCF)OCF and TERFee dragHow charges add up
In plain English
Invesco NASDAQ Biotech UCITS ETF is an exchange-traded fund (ETF) from Invesco, launched in 2014.
It tracks the NASDAQ / Biotechnology.
You buy and sell it through a share-dealing account or platform during stock-market hours, like a share.
Its ongoing charge is 0.4% a year — about £40 a year on every £10,000 invested, taken from the fund's value rather than billed to you.
Income from its investments is reinvested inside the fund, so it shows up as a rising price rather than cash paid to you.
Healthcare: Pharmaceutical, biotech and medical-equipment companies.
Terms:ETFIndex fundUCITSAccumulating or incomeShare classISIN
Key facts
- Ticker
- SBIX
- ISIN
- IE00BQ70R696
- Also listed as
- SBIO (London Stock Exchange, US dollars), NBTK (Xetra, euros)
- Provider
- Invesco
- Tracks
- NASDAQ / Biotechnology
- Structure
- ETF
- An exchange-traded fund: bought and sold on the stock exchange through the day, like a share.
- Income
- Accumulating
- Income is reinvested inside the fund, so it shows up as a rising price rather than cash paid to you.
- Ongoing charge
- 0.40% a year · about £40 on £10,000
- Fund size
- £503m
- Launched
- Domicile
- Ireland
- UK reporting fund status
- Yes — on HMRC’s list of reporting funds (list of )
- Reporting fund since . What reporting fund status means
- Can usually be held in
- ISA and SIPP
- Check with your platform: each decides which funds it offers.
- Currency hedged
- No
- Price currency
- Pounds (GBP)
- Category
- Healthcare
Price chart
Over the last year, the closing price went from £43.97 on 14/11/2025 to £56.52 on 13/11/2026 (+28.6%). The lowest close shown was £43.87 on 27/03/2026 and the highest £57.06 on 30/10/2026.
One close a week. Before 06/08/2026 the closes are from the weekly price history for this listing; from then on, the closing prices we have recorded.
As of , at least 15 min delayed
Five years of prices, and after inflation
65 weekly closes, from 15/08/2025 to 13/11/2026. The same history in November 2026 pounds, adjusted with CPIH inflation.
Create a free account to see the 5-year price chart and the after-inflation chart
Sign-up takes an email address. There is no card to enter and nothing to pay.
How we work it out:Prices and returnsNAV and price
What it holds
- Holdings
- 239
- 244 reported in all
- Ten largest
- 48.2%
- of the whole fund
- Effective number of holdings
- 29
- As concentrated as this many equal-sized holdings (how it is worked out)
- Largest holding
- 9.0%
- Gilead Sciences
Top 10 holdings
| Rank# | Holding | Weight as a percentage of the fund |
|---|---|---|
| 1 | Gilead SciencesGILD | 9.03% |
| 2 | AmgenAMGN | 8.55% |
| 3 | Vertex PharmaceuticalsVRTX | 7.84% |
| 4 | Regeneron PharmaceuticalsREGN | 6.19% |
| 5 | ModernaMRNA | 5.95% |
| 6 | Revolution MedicinesRVMD | 2.43% |
| 7 | BiogenBIIB | 2.38% |
| 8 | IlluminaILMN | 2.04% |
| 9 | Royalty Pharma · Class ARPRX | 1.97% |
| 10 | Roivant SciencesROIV | 1.86% |
As of , holdings as published
Where it invests
The portfolio by sector, country and type of asset, as a share of the whole fund. Bonds, cash and positions without a classification are shown as they come, not guessed.
By country
- United States93.9%
- Belgium1.8%
- Denmark1.4%
- Canada0.6%
- Germany0.6%
- Netherlands0.4%
- France0.3%
- Switzerland0.3%
- Other countries0.7%
See the full portfolio
Every holding with search and filters, the whole breakdown by sector, country and type of asset, a map of the 100 largest and what changed since .
All holdings
The fund publishes 244 holdings; the ten largest make up 48.2% of it.
Create a free account to see the full holdings list
Sign-up takes an email address. There is no card to enter and nothing to pay.
Sector split
As a share of the whole fund. 93.3% of it is classified by sector; bonds, cash and positions that cannot be matched are left out rather than guessed.
- Health Technology91.0%
- Commercial Services1.3%
- Technology Services0.9%
- Health Services0.1%
Holdings:Compare what it holds with another fundHoldings overlapHow overlap is measured
Funds tracking the same index
3 funds track NASDAQ / Biotechnology, this one included and share classes counted once; their ongoing charges range from 0.35% to 0.40% a year (13/11/2026).
| Fund | Charge | 1 year | 3 years | 5 years |
|---|---|---|---|---|
| Invesco NASDAQ Biotech UCITS ETFThis fundAccumulating · 0.40% a year | 0.40% | +33.3% | +86.5% | +57.3% |
| iShares NASDAQ US Biotechnology UCITS ETFAccumulating · 0.35% a year | 0.35% | +33.2% | +86.4% | +57.1% |
| iShares NASDAQ US Biotechnology UCITS ETF DistDistributing · 0.35% a year | 0.35% | +34.0% | +86.5% | +57.5% |
As of
Nasdaq Biotechnology funds compared: charges, sizes and share classes
Read more:Index fundsTracking differenceHow funds are compared
Risk and return in depth
Sharpe, Sortino and Calmar ratios
Sharpe, Sortino and Calmar ratios over 1 year, from weekly returns in pounds.
With a free accountLargest falls and recoveries
The 3 largest falls since August 2025, in pounds, with how many weeks each took to reach its low and to recover.
With a free account
Create a free account to see the risk ratios and each large fall and its recovery
Sign-up takes an email address. There is no card to enter and nothing to pay.
Questions people ask
What is the ongoing charge of SBIX?
The ongoing charge of SBIX is 0.40% a year — about £40 a year on every £10,000 invested, taken from the fund’s value rather than billed to you. Platform and dealing fees are charged separately. Ongoing charge of Invesco NASDAQ Biotech UCITS ETF 0.40% a year. Compared on 14/11/2026, 7 of the 28 other healthcare funds charge more, 2 the same and 19 less (share classes counted once).
What does SBIX track?
SBIX tracks the NASDAQ / Biotechnology.
Is SBIX accumulating or distributing?
SBIX is accumulating: income is reinvested inside the fund, so it shows up as a rising price rather than cash paid to you.
What is the ISIN of SBIX?
The ISIN of SBIX is IE00BQ70R696. An ISIN identifies one exact share class of a fund; SBIX is its ticker on the London Stock Exchange. The same share class is also listed as SBIO (London Stock Exchange, US dollars) and NBTK (Xetra, euros).
What does SBIX hold?
As of 12/11/2026, SBIX holds 244 positions, according to its published holdings. The largest is Gilead Sciences at 9.03% of the fund; the ten largest make up 48.2%. Its ten largest holdings are Gilead Sciences (9.03%), Amgen (8.55%), Vertex Pharmaceuticals (7.84%), Regeneron Pharmaceuticals (6.19%), Moderna (5.95%), Revolution Medicines (2.43%), Biogen (2.38%), Illumina (2.04%), Royalty Pharma · Class A (1.97%) and Roivant Sciences (1.86%).
What were SBIX’s returns in each of the last five years?
Calendar-year returns of SBIX in pounds (price, with income reinvested in the fund): 2026 to 13/11/2026 +28.8%. Past performance is not a guide to future returns.
How has SBIX done after inflation?
Over the five years to 13/11/2026 SBIX’s total return was +57.3%, or +22.8% after UK CPIH inflation. Past performance is not a guide to future returns.
Similar funds
- XWHSXtrackers MSCI World Health Care UCITS ETF0.25% a year · £3.4bn
- IHCUiShares S&P 500 Health Care Sector UCITS ETF0.15% a year · £2.7bn
- DRDRiShares Healthcare Innovation UCITS ETF0.40% a year · £1.3bn
- XSHCXtrackers MSCI USA Health Care UCITS ETF0.12% a year · £1.2bn
- BTEKiShares NASDAQ US Biotechnology UCITS ETF0.35% a year · £1.0bn
- CH5Amundi STOXX Europe 600 Healthcare UCITS ETF -Acc- Capitalisation0.30% a year · £833m
- ESIHiShares MSCIEurope Health Care Sector UCITS ETF AccumEUR0.18% a year · £798m
- 0DW6Amundi MSCI World Health Care UCITS ETF EUR ACC0.30% a year · £792m
Fund documents and methods
Methodology:ReturnsCategoriesAll methods
A machine-readable copy of this page: Markdown.